Media coverage about Delcath Systems (NASDAQ:DCTH) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Delcath Systems earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 45.6019477159148 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- Delcath Systems, Inc. (DCTH) registers a price change of -0.49% while Dextera Surgical Inc. (DXTR) finishes with a … – Stocks Gallery (stocksgallery.com)
- Today’s Hot Mover: Delcath Systems, Inc., (NASDAQ: DCTH) – Stock Watch (stocksnewstimes.com)
- Hot Stock in Focus: Delcath Systems, Inc. (NASDAQ: DCTH) – Alpha Beta Stock (alphabetastock.com)
- Delcath Systems, Inc. (DCTH)- Stocks Ringing Performance Alarms – NASDAQ Times (nasdaqtimes.com)
- Delcath Systems, Inc. (DCTH)- Stocks Flirting with Minor Gains and Losses – NASDAQ Times (nasdaqtimes.com)
Delcath Systems (NASDAQ:DCTH) traded up 0.2646% on Tuesday, hitting $0.0379. The stock had a trading volume of 944,921 shares. Delcath Systems has a 52-week low of $0.02 and a 52-week high of $3.27. The stock’s 50-day moving average is $0.08 and its 200-day moving average is $0.09. The company’s market cap is $16.09 million.
COPYRIGHT VIOLATION NOTICE: “Delcath Systems (DCTH) Given Media Sentiment Rating of 0.14” was originally reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/delcath-systems-dcth-receiving-somewhat-favorable-media-coverage-accern-reports/1698844.html.
Delcath Systems Company Profile
Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).
Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with our FREE daily email newsletter.